# Pharmacoanalytical Shared Resource

> **NIH NIH P30** · OHIO STATE UNIVERSITY · 2020 · $88,032

## Abstract

CORE-012: PHARMACOANALYTICAL SHARED RESOURCE (PhASR)
PROJECT SUMMARY / ABSTRACT
The Ohio State University Comprehensive Cancer Center (OSUCCC) Pharmacoanalytical Shared Resource
(PhASR) provides critical support to OSUCCC's robust drug development efforts, highlighted by a robust
clinical trials program that has increased therapeutic accruals by 51% during the prior grant period and notable
because the OSUCCC is one of only five institutions with both an NCI clinical trials UM1 Phase I grant and N01
Phase II contract. PhASR's Specific Aims are: 1) development and validation of new assays to quantify drugs
and metabolites in biological specimens; 2) quantify drug and metabolite levels in biological matrices, and
conduct pharmacokinetic (PK) and pharmacodynamic (PD) studies for incorporation into pre-clinical and
clinical decision-making; and, 3) provide expertise in PK/PD study design and data interpretation to support
submission of clinical protocols, grants, and publications. PhASR is directed by Dr. Mitchell Phelps (LR) and
the Senior Faculty Advisor is Dr. Michael Grever (LR). Located within the Biomedical Research Tower, PhASR
is accessible to most OSUCCC cancer researchers, and is directly across from the new James Cancer
Hospital. Outstanding institutional support is provided by the OSUCCC, College of Pharmacy, and Center for
Clinical and Translational Science. Major equipment in PhASR includes 5 LC-MS systems ideally suited for
drug quantification and metabolite identification, namely a quadrupole-time-of-flight, an ion trap, and three
triple-quadrupole mass spectrometers, supported by ultra-high pressure liquid chromatography systems and
automated sample processing for high throughput analysis. The Dionex RSLCnano/TSQ Quantiva mass
spectrometer is the most advanced on the market. During the prior grant period, PhASR provided services to
50 OSUCCC members, representing all 5 programs, and developed more than 120 assays. It has provided
14,416 hours of services as well as assays for 2024 samples during the prior grant period. PhASR has
contributed to over 79 publications (7 with an impact factor >10), contributed data for 41 grant applications and
has supported 53 clinical trials. In the future, the PhASR will enhance its support for the OSUCCC Drug
Development Institute (DDI), and increase both its pharmacodynamic and modeling services, and recruit
additional faculty in pharmaceutics. The annual budget is $744,732, yet the CCSG request is $77,729. The
PhASR leverages extensive institutional support and seeks only 10.4% support from CCSG funds. The
Pharmacoanalytical Shared Resource is part of the Analytics Grouping.

## Key facts

- **NIH application ID:** 9843871
- **Project number:** 5P30CA016058-44
- **Recipient organization:** OHIO STATE UNIVERSITY
- **Principal Investigator:** Mitch A Phelps
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $88,032
- **Award type:** 5
- **Project period:** — → —

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9843871

## Citation

> US National Institutes of Health, RePORTER application 9843871, Pharmacoanalytical Shared Resource (5P30CA016058-44). Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/grant/nih/9843871. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*